Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
EDX Medical Group PLC - London-based developer of diagnostics products to help predict disease risk - Announces European cancer biomarker programme collaboration with Tianjin Bioscience Diagnostics Technology Co Ltd. The programme aims to improve access to reliable and cost-effective tests for cancers in the UK and Europe. EDX Medical will ‘conduct validation studies and submit data on individual tests to UK and EU Authorities for regulatory approval,’ it says. Tianjin Bioscience installed two automated digital chemiluminescence immunoassay instruments at EDX’s laboratory in Cambridge. The instruments have a capacity to process up to 250,000 tests per year.
‘The automation and combination of tests means improved flexibility, enhanced data and rapid delivery of test results,’ says EDX Medical Chief Executive Officer Mike Hudson.
EDX Medical started trading on the AQSE last week following a £12 million reverse takeover by special purpose acquisition company TECC Capital PLC.
Current stock price: 5.25 pence for £13.2 million market capitalisation
Copyright 2022 Alliance News Limited. All Rights Reserved.